Research Use Only Notice: BPC-157 is a research peptide intended for in-vitro and animal research applications only. It is not FDA-approved as a drug or therapy. Nothing in this article constitutes medical advice, treatment recommendation, or guidance for human consumption.
BPC-157 — short for Body Protection Compound-157 — is one of the most extensively studied research peptides in modern compound science. A 15-amino-acid synthetic peptide originally identified in gastric juice, BPC-157 has been the focus of hundreds of published animal and in-vitro studies investigating tissue repair, anti-inflammatory effects, and signaling pathway modulation. This complete guide from the chemistry team at OPS Peptide Science walks through what BPC-157 is, what the research literature documents, how researchers handle it in protocols, and where it sits in the broader peptide research catalog.
For the foundational research-workflow protocols this guide assumes, see our companion guides on how to reconstitute peptides, how to inject peptides, and peptide storage and refrigeration.
What Is BPC-157?
BPC-157 is a 15-amino-acid synthetic peptide derived from a sequence originally identified in human gastric juice. The name “Body Protection Compound” reflects the research history — BPC-157 was first studied in gastrointestinal protection contexts before researchers documented its broader effects across tissue types.
Key facts about BPC-157:
- Chemical class — short peptide (15 amino acids), synthetic version of a naturally occurring gastric sequence
- Molecular weight — approximately 1419 Da
- Sequence — Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (single-letter: GEPPPGKPADDAGLV)
- Form — typically supplied as lyophilized (freeze-dried) powder; reconstituted with bacteriostatic water for research administration
- Half-life — short, approximately 4-6 hours in research models
- Stability — stable at -20°C as lyophilized powder for 18-24 months; reconstituted solutions stable for 21-28 days refrigerated

BPC-157 is one of the most-searched research peptides because the published literature is substantial — hundreds of animal studies and in-vitro experiments document effects across multiple research models. The compound is not FDA-approved and is sold legally in the US only as a research chemical under research-use-only labeling.
BPC-157 Structure and Chemistry
The BPC-157 sequence is unusual for a research peptide. Most synthetic peptides are designed analogs of larger hormones (insulin fragments, growth hormone secretagogues). BPC-157 instead originates from the protein BPC (Body Protection Compound) found in gastric juice. The “157” in its name refers to the partial sequence position from the parent BPC protein.
Structurally significant features:
- High proline content — five proline residues (positions 3, 4, 5, 8) give the peptide structural rigidity and unusual resistance to enzymatic degradation
- Gastric origin — the parent protein evolved to function in the stomach environment, giving BPC-157 unusual stability under acidic and enzymatic conditions
- Stable in gastric environment — published research has documented some oral bioavailability for BPC-157 due to this gastric stability, though most research protocols use injection administration
This proline-rich sequence is part of why BPC-157 became such an active research compound — its stability profile is unusually favorable for a small peptide, allowing reliable research dosing protocols.
How BPC-157 Works in Research (Mechanism)
The BPC-157 mechanism is not characterized by a single receptor binding event — research has documented effects across multiple biological pathways, which is unusual for synthetic peptides and contributes to its broad research interest. Documented pathways include:
- VEGF (Vascular Endothelial Growth Factor) modulation — BPC-157 has been documented to upregulate VEGF expression, which drives angiogenesis (new blood vessel formation)
- Nitric oxide system interactions — research literature shows BPC-157 influences both NO synthesis and the NO system’s vasodilation effects
- Growth hormone receptor expression — published studies have documented increased growth hormone receptor expression in tendon and other tissue research models
- Inflammatory pathway modulation — measured reductions in pro-inflammatory cytokines (IL-6, TNF-α) in animal injury models
- Dopaminergic system effects — some research literature documents effects on dopamine systems, suggesting central nervous system activity
- Serotonin system effects — published animal research has measured serotonin modulation in some research models

The multi-pathway nature of the BPC-157 mechanism is what makes the compound interesting in research contexts — it doesn’t fit the typical one-receptor-one-effect model of most synthetic peptides. The BPC-157 research literature on PubMed documents these pathways across hundreds of studies, though the overall mechanistic picture remains incomplete in published literature.
BPC-157 Research Applications
Research literature documents BPC-157 effects across several major application areas:
Tendon and Ligament Research
The most extensively studied BPC-157 application is in tendon and ligament repair research. Multiple animal models — Achilles tendon transection, medial collateral ligament injury, muscle crush — have documented faster repair markers, improved tensile strength recovery, and accelerated cell migration in BPC-157-treated subjects compared to controls.
Gastrointestinal Research
BPC-157’s gastric origin gives it natural research relevance for GI applications. Published research includes ulcer healing models, inflammatory bowel disease models, and gastrointestinal barrier function studies. The compound shows measurable effects on mucosal healing markers in animal models.
Muscle and Soft Tissue Repair
Beyond tendons, BPC-157 research extends into skeletal muscle injury models, soft tissue inflammation, and post-traumatic recovery markers in animal subjects. Published studies have documented effects on muscle satellite cell activity and fiber regeneration markers.
Bone Research
Animal models of bone fracture and bone graft research have documented BPC-157 effects on bone healing markers, callus formation, and bone density endpoints. The mechanism appears to involve the VEGF angiogenesis pathway that supports bone tissue regeneration.

Neural Research
Smaller but growing research body on BPC-157 effects in neural injury models, traumatic brain injury research, and neuroprotection contexts. The dopaminergic and serotonergic system effects suggest broader CNS activity than was originally characterized.
BPC-157 Research Studies and Literature
The BPC-157 research literature spans approximately 30 years, originating primarily from research programs at the University of Zagreb (Croatia) and expanding to research groups worldwide. The published research base includes:
- Hundreds of animal studies — predominantly rodent models, with smaller numbers in larger animals
- In-vitro cell culture studies — fibroblast, endothelial, and muscle cell research
- Pharmacokinetic characterization — half-life, distribution, and clearance data in animal models
- Mechanism investigation — receptor binding studies, pathway analysis, gene expression research
- Comparative studies — BPC-157 compared to other tissue-repair compounds in similar research models
Notably absent: large-scale human clinical trials. BPC-157 has not completed the FDA approval pipeline. Research remains primarily animal and in-vitro, with the compound sold in the United States only as a research chemical for laboratory study.
BPC-157 Dosing in Research Models
Research dosing of BPC-157 varies significantly across published studies. Common patterns in the literature:
- Animal model dosing — typically reported in μg/kg body weight, with daily or twice-daily subcutaneous administration
- In-vitro cell culture concentrations — typically reported in nM or μM in published research
- Protocol duration — most published studies run 1-4 weeks of consistent dosing to capture tissue-level effects
- Administration route — subcutaneous injection is the most common in published animal research, with some studies using intramuscular or oral administration
Research protocols should always reference published methodology for the specific research model. The optimal dosing varies by animal species, research endpoint, and specific injury or condition being studied. For practical research-workflow setup, see our guide on what size syringe for peptides for the standard equipment used in subcutaneous BPC-157 administration.
BPC-157 Storage and Stability
BPC-157 stability profile is among the more favorable for small research peptides, owing to its proline-rich structure:
| Storage Condition | Form | Stability Window |
|---|---|---|
| -80°C (ultra-low freezer) | Lyophilized powder | 3-5+ years |
| -20°C (standard lab freezer) | Lyophilized powder | 18-24 months |
| 2-8°C (refrigerated) | Lyophilized powder | 6-12 months |
| Room temperature | Lyophilized powder | 2-4 weeks for transit |
| 2-8°C (refrigerated) | Reconstituted in BAC water | 21-28 days |
For detailed stability and storage protocols, see our guide on how long do peptides last at room temperature.
BPC-157 + TB-500 Combination Research (Wolverine Stack)
One of the most-discussed BPC-157 research applications is its combination with TB-500 (Thymosin Beta-4) — popularly called the “Wolverine Stack” in research and biohacking discussions. The rationale for combination research:
- Different mechanisms — BPC-157 acts on VEGF/angiogenesis pathways; TB-500 acts on actin/cell migration
- Potentially additive effects — the two pathways could combine without overlapping, producing additive tissue-repair effects
- Documented in published research — both compounds appear in combination protocols across animal research studies
Research design for combination studies requires separate reconstitution, separate injection sites, and careful documentation of each compound’s contribution. See our companion overview on peptides for healing and recovery for the broader context on these compounds.

How to Identify Quality BPC-157
The research peptide market includes vendors of varying quality. Quality BPC-157 research-grade peptide has these characteristics:
- 99%+ purity confirmed by HPLC-MS analysis — purity below this level can compromise research data through unknown contaminants
- Per-lot Certificate of Analysis — each batch independently tested and documented, not just a generic spec sheet
- Documented mass spectrometry identity — confirms the compound is actually BPC-157 and not a degradation product or contaminant
- Chain-of-custody documentation — traceable from manufacturer to fulfillment
- Properly lyophilized appearance — should be a clean white cake at the bottom of the vial, not discolored or melted
- Research-use-only labeling — required by US regulations for non-FDA-approved compounds
At OPS Peptide Science, every BPC-157 vial ships with a unique BIOVIRIDIAN COA code. Customers can verify the Certificate of Analysis for their specific lot before opening the vial — a key trust signal that distinguishes documented research-grade compound from unverified market peptides.
BPC-157 Regulatory Status
BPC-157 occupies a specific position in US regulatory frameworks:
- Not FDA-approved — has not completed clinical trials required for human drug approval
- Removed from 503A compounding list in 2023 — pharmacies can no longer compound BPC-157 for prescription use
- Added to WADA Prohibited List in 2023 — banned in WADA-governed athletic competition under category S0
- Legal as research chemical — sold in the US for in-vitro and animal research under research-use-only labeling
- Not DEA-scheduled — no controlled substance status
For the complete legal framework around peptides like BPC-157, see our detailed guide on are peptides illegal. According to NIH research literature, BPC-157 remains an active area of pre-clinical investigation despite the regulatory restrictions on human use.

FAQ
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a 15-amino-acid synthetic peptide derived from a sequence originally identified in gastric juice. It is one of the most extensively studied research peptides, with hundreds of animal and in-vitro studies documenting effects on tissue repair, angiogenesis, anti-inflammatory pathways, and gastrointestinal research models.
Is BPC-157 legal in the US?
BPC-157 is legally sold in the US as a research chemical for in-vitro and animal study, under research-use-only labeling. It is not FDA-approved for human use and was removed from the 503A pharmacy compounding list in 2023. WADA has prohibited it in athletic competition since 2023.
How long does BPC-157 take to work in research?
Research timeline varies by endpoint and model. Acute anti-inflammatory effects appear within days in animal research models. Tissue-level repair effects (tendon, ligament, muscle healing) typically require 2-4 weeks of consistent dosing. Specific timelines depend on the injury model and the research endpoint being measured.
Can BPC-157 be taken orally in research?
Research literature documents some oral activity for BPC-157 due to its gastric-protein origin and proline-rich structure, which resists digestive degradation better than most peptides. However, most published research protocols use subcutaneous injection because injection bioavailability is more reliable and reproducible than oral.
What’s the difference between BPC-157 and TB-500?
Both are research peptides studied in tissue-repair contexts, but they act through different mechanisms. BPC-157 acts on VEGF/angiogenesis and multiple signaling pathways. TB-500 (Thymosin Beta-4) acts on actin sequestration and cell migration. Combination research (the “Wolverine Stack”) explores whether the two produce additive effects.
How do I store BPC-157?
Lyophilized BPC-157 powder stores at -20°C for 18-24 months. Reconstituted BPC-157 in bacteriostatic water stores at 2-8°C for 21-28 days. See our complete guide on peptide refrigeration requirements for detailed storage protocols.
Where can I buy research-grade BPC-157?
Research-grade BPC-157 is sold by research peptide suppliers operating under research-use-only labeling. Quality criteria include 99%+ HPLC-MS verified purity, per-lot Certificates of Analysis, and traceable chain-of-custody documentation. Browse the OPS Peptide Science catalog for verified research-grade BPC-157.
BPC-157 occupies a unique position in modern research peptide science — a small synthetic peptide with a substantial published literature base, an unusually favorable stability profile, and documented effects across multiple research applications. For researchers studying tissue repair, gastrointestinal models, or related endpoints, BPC-157 remains one of the most-referenced compounds in the modern research catalog.
For research-grade BPC-157 backed by per-lot Certificates of Analysis and full HPLC-MS purity documentation, browse the OPS Peptide Science catalog, visit the OPS Peptide Science homepage for the full product overview, or verify a specific lot using its COA code.
Author: Shane Straight, Principal Chemist, OPS Peptide Science
Reviewed: May 2026





